USD 2.8
(4.87%)
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2023 | 1.74 Million USD | -16.06% |
2022 | 2.07 Million USD | -13.34% |
2021 | 2.39 Million USD | -30.65% |
2020 | 3.45 Million USD | 3071.74% |
2019 | 108.87 Thousand USD | -16.45% |
2018 | 130.31 Thousand USD | -88.94% |
2017 | 1.17 Million USD | 88026.7% |
2016 | 1337.00 USD | 0.0% |
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2024 Q2 | 1.59 Million USD | -12.29% |
2024 Q1 | 1.81 Million USD | 4.33% |
2023 Q2 | 1.93 Million USD | 18.74% |
2023 FY | 1.74 Million USD | -16.06% |
2023 Q4 | 1.74 Million USD | -2.02% |
2023 Q3 | 1.77 Million USD | -8.13% |
2023 Q1 | 1.62 Million USD | -21.46% |
2022 FY | 2.07 Million USD | -13.34% |
2022 Q4 | 2.07 Million USD | 50.97% |
2022 Q3 | 1.37 Million USD | -11.15% |
2022 Q2 | 1.54 Million USD | -24.44% |
2022 Q1 | 2.04 Million USD | -14.5% |
2021 Q2 | 2.63 Million USD | -15.17% |
2021 Q1 | 3.1 Million USD | -10.05% |
2021 FY | 2.39 Million USD | -30.65% |
2021 Q4 | 2.39 Million USD | -11.75% |
2021 Q3 | 2.71 Million USD | 2.98% |
2020 FY | 3.45 Million USD | 3071.74% |
2020 Q2 | 90.55 Thousand USD | -3.85% |
2020 Q1 | 94.18 Thousand USD | -13.49% |
2020 Q4 | 3.45 Million USD | 4130.28% |
2020 Q3 | 81.62 Thousand USD | -9.86% |
2019 FY | 108.87 Thousand USD | -16.45% |
2019 Q4 | 108.87 Thousand USD | 35.03% |
2019 Q3 | 80.62 Thousand USD | -34.61% |
2019 Q2 | 123.29 Thousand USD | -4.83% |
2019 Q1 | 129.55 Thousand USD | -0.58% |
2018 Q3 | 501.56 Thousand USD | 0.0% |
2018 Q4 | 130.31 Thousand USD | -74.02% |
2018 Q1 | - USD | -100.0% |
2018 FY | 130.31 Thousand USD | -88.94% |
2017 FY | 1.17 Million USD | 88026.7% |
2017 Q4 | 1.17 Million USD | 0.0% |
2016 FY | 1337.00 USD | 0.0% |
Name | Total Liabilities | Total Liabilities Difference |
---|---|---|
Aclaris Therapeutics, Inc. | 40.22 Million USD | 95.67% |
Applied DNA Sciences, Inc. | 8.77 Million USD | 80.158% |
Aspira Women's Health Inc. | 8.62 Million USD | 79.808% |
Biodesix, Inc. | 94.51 Million USD | 98.157% |
bioAffinity Technologies, Inc. | 3.36 Million USD | 48.253% |
bioAffinity Technologies, Inc. | 3.36 Million USD | 48.253% |
Bionano Genomics, Inc. | 118.24 Million USD | 98.527% |
CareDx, Inc | 223.28 Million USD | 99.22% |
Check-Cap Ltd. | 1.33 Million USD | -30.973% |
Castle Biosciences, Inc. | 86.54 Million USD | 97.987% |
DarioHealth Corp. | 38.24 Million USD | 95.445% |
Exact Sciences Corporation | 3.32 Billion USD | 99.948% |
Fulgent Genetics, Inc. | 139.82 Million USD | 98.754% |
Guardant Health, Inc. | 1.62 Billion USD | 99.893% |
ICON Public Limited Company | 7.74 Billion USD | 99.978% |
IDEXX Laboratories, Inc. | 1.77 Billion USD | 99.902% |
Illumina, Inc. | 4.36 Billion USD | 99.96% |
Intelligent Bio Solutions Inc. | 5.59 Million USD | 68.87% |
iSpecimen Inc. | 6.07 Million USD | 71.341% |
Standard BioTools Inc. | 159.86 Million USD | 98.91% |
MDxHealth SA | 121.92 Million USD | 98.571% |
23andMe Holding Co. | 206.64 Million USD | 99.157% |
Medpace Holdings, Inc. | 1.09 Billion USD | 99.841% |
Myriad Genetics, Inc. | 312.9 Million USD | 99.443% |
Mainz Biomed B.V. | 12.15 Million USD | 85.675% |
ENDRA Life Sciences Inc. | 1.09 Million USD | -59.059% |
NeoGenomics, Inc. | 739.69 Million USD | 99.765% |
Neogen Corporation | 1.44 Billion USD | 99.879% |
Inotiv, Inc. | 588.04 Million USD | 99.704% |
Natera, Inc. | 691.79 Million USD | 99.748% |
OpGen, Inc. | 13.44 Million USD | 87.043% |
OPKO Health, Inc. | 622.47 Million USD | 99.72% |
Psychemedics Corporation | 6.59 Million USD | 73.599% |
Prenetics Global Limited | 44.01 Million USD | 96.042% |
Prenetics Global Limited | 44.01 Million USD | 96.042% |
Precipio, Inc. | 3.67 Million USD | 52.562% |
Personalis, Inc. | 95.65 Million USD | 98.179% |
RadNet, Inc. | 2.07 Billion USD | 99.916% |
Sera Prognostics, Inc. | 25.28 Million USD | 93.11% |
Sotera Health Company | 2.68 Billion USD | 99.935% |
Neuronetics, Inc. | 81.64 Million USD | 97.866% |
Star Equity Holdings, Inc. | 21.67 Million USD | 91.963% |
Star Equity Holdings, Inc. | 21.67 Million USD | 91.963% |
Trinity Biotech plc | 83.38 Million USD | 97.911% |
T2 Biosystems, Inc. | 62.83 Million USD | 97.228% |
Twist Bioscience Corporation | 152.97 Million USD | 98.861% |
Exagen Inc. | 34.25 Million USD | 94.914% |